aTyr Pharma, Inc. (NASDAQ:LIFE) Shares Sold by Stonepine Capital Management LLC

Stonepine Capital Management LLC lowered its position in aTyr Pharma, Inc. (NASDAQ:LIFE - Free Report) by 89.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 482,258 shares of the biotechnology company's stock after selling 4,144,366 shares during the quarter. aTyr Pharma accounts for approximately 0.3% of Stonepine Capital Management LLC's holdings, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned about 0.82% of aTyr Pharma worth $680,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Northern Trust Corp lifted its holdings in aTyr Pharma by 27.5% in the 4th quarter. Northern Trust Corp now owns 100,102 shares of the biotechnology company's stock worth $141,000 after buying an additional 21,583 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in aTyr Pharma in the 4th quarter worth $202,000. Granite Bay Wealth Management LLC acquired a new stake in shares of aTyr Pharma in the 4th quarter valued at about $25,000. American Century Companies Inc. lifted its position in shares of aTyr Pharma by 55.6% during the third quarter. American Century Companies Inc. now owns 22,080 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 7,889 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of aTyr Pharma during the third quarter worth about $44,000. Institutional investors and hedge funds own 61.72% of the company's stock.

aTyr Pharma Stock Performance

NASDAQ LIFE traded down $0.11 during trading hours on Tuesday, reaching $1.72. The company's stock had a trading volume of 787,565 shares, compared to its average volume of 537,326. The company has a current ratio of 6.27, a quick ratio of 6.27 and a debt-to-equity ratio of 0.02. The business has a 50-day simple moving average of $1.85 and a 200 day simple moving average of $1.53. aTyr Pharma, Inc. has a 52 week low of $1.08 and a 52 week high of $2.70. The stock has a market cap of $116.53 million, a PE ratio of -1.79 and a beta of 1.25.

aTyr Pharma (NASDAQ:LIFE - Get Free Report) last issued its earnings results on Thursday, March 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.02). Equities research analysts predict that aTyr Pharma, Inc. will post -0.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of aTyr Pharma in a research report on Friday, March 15th. Royal Bank of Canada reduced their price target on shares of aTyr Pharma from $19.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, March 15th. Finally, StockNews.com cut shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, December 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $23.67.

aTyr Pharma Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.